BOB NELSEN
Co-Founder & Managing Director | ARCH Venture Partners

Bob Nelsen is a Co-Founder and Managing Director of ARCH Venture Partners. Here, he played a significant role in the early sourcing, financing and development of over 100 companies (23 have reached valuations exceeding $1 billion). His seed and early-stage investments include Illumina (ILMN), Alnylam Pharmaceuticals (ALNY), Juno Therapeutics (JUNO), Unity Biotechnology (UBX), Sienna Biopharmaceuticals (SNNA), Vir Biotechnology (VIR), Agios Pharmaceuticals (AGIO), Sage Therapeutics (SAGE), GRAIL, Ikaria, Kythera Biopharmaceuticals (KYTH), Receptos (RCPT), Aviron (AVIR), Denali Therapeutics (DNLI), Prime Medicine, Beam Therapeutics (BEAM), NetBot, Bluebird Bio (BLUE), R2 Technology, XenoPort (XNPT), Caliper Life Sciences (CALP), Trubion Pharmaceuticals (TRBN), Adolor (ADLR), deCODE Genetics, Array BioPharma (ARRY), Editas (EDIT), IDUN Pharmaceuticals, Classmates.com, Hua Medicine, Fate Therapeutics (FATE), Rubius Therapeutics (RUBY), KSQ Therapeutics, WuxiNextCODE, and Everyday Learning Corporation.

Mr. Nelsen is a Director of Vir Bio, GRAIL, Sana Biotechnology, Beam Therapeutics, Prime Medicine, Lyell, Unity Biotechnology, Denali Therapeutics, Karuna Therapeutics, insitro, Maze Therapeutics, Inc., Encoded Therapeutics and serves as Chairman of Hua Medicine, among others.

Previously, he served as a Trustee of the Fred Hutchinson Cancer Research Institute, the Institute for Systems Biology, and was a Director of the National Venture Capital Association.

Mr. Nelsen holds an MBA from the University of Chicago and a BS in Economics and Biology from the University of Puget Sound.